VEGFA and neoplasm: In fact, LRTs induce tumor ischemia, resulting in a slight increase in VEGF and other hypoxia-induced factors, whereas the well-known antiangiogenetic activity of sorafenib inhibits specific receptors of such molecules [22,23].